Russell Z. Szmulewitz to Survival Rate
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Survival Rate.
Connection Strength
0.091
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761.
Score: 0.033
-
Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
Score: 0.031
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 2017 03; 77(4):385-395.
Score: 0.027